EQS-Adhoc: PharmaSGP Holding SE decides on public share buyback offer to buy back own shares up to a maximum of 594,405 shares Page 1

EQS-Ad-hoc: PharmaSGP Holding SE / Keywords: Share buyback
PharmaSGP Holding SE decides to launch public share buyback offer to repurchase own shares for up to 594,405 shares

12-09-2024 / 08:10 CET/CEST
Disclosure of inside information pursuant to Article 17 MAR of Regulation (EU) No 596/2014, sent by EQS News – a service of EQS Group AG.
The publisher is solely responsible for the content of this communication.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. SEE IMPORTANT NOTICE AT THE END OF AD-HOC RELEASE.

Disclosure of inside information pursuant to Article 17 paragraph 1 of Regulation (EU) No 596/2014 (Market Abuse Regulation – MAR)

PharmaSGP Holding SE decides to launch public share buyback offer to repurchase own shares for up to 594,405 shares

Gräfelfing, Germany, September 12, 2024 – The board of directors of PharmaSGP Holding SE (the “Company”) (ISIN DE000A2P4LJ5 / WKN A2P4LJ) has today, with the approval of the supervisory board, decided to repurchase, using the authorization of the annual general meeting of June 26, 2024, a maximum of 594,405 shares of the Company (corresponding to a maximum of 4.95% of the registered share capital of the Company (Capital stock)) by means of a public offer to buy back own shares for a consideration of EUR 21.45 per share. The current intention is to redeem the shares thus bought back and to reduce the share capital accordingly.

The Company’s two largest shareholders, FUTRUE GmbH, which holds approximately 73.6% of the Company’s share capital, and MVH Beteiligungs- und Beratungs-GmbH, which holds approximately 7.8% of the Company’s share capital, have irrevocably committed themselves to the Company not to accept the offer to buy back any of the Company’s own shares for any shares they hold directly or indirectly.

The acceptance period will commence on 13 September 2024 at 00:00 (CEST) and is expected to end on 26 September 2024 at 24:00 (CEST). If the number of shares tendered for the share buyback offer exceeds 594,405, the acceptance statements will be considered proportionally, i.e. in a ratio of the 594,405 shares to the total number of shares tendered for the share buyback offer. Further information on the public share buyback offer can be found in the offer document, which will be published prior to the commencement of the acceptance period on the Company’s website (https://www.pharmasgp.com) under the heading “Investor Relations – The share – Share buy-backs – Share buy-back 2024” and in the German Federal Official Gazette at www.bundesanzeiger.de.